Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 14/20 | 0.61 |
| ▸ | KDM5C | P41229 | 8/20 | 0.61 |
| ▸ | KDM5A | P29375 | 7/20 | 0.61 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.61 |
| ▸ | KDM4A | O75164 | 2/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.46 |
| ▸ | JMJD6 | Q6NYC1 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15636647 | 0.90 | KDM5B (0.58) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL15994209 | 0.87 | KDM5B (0.53) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL15994300 | 0.86 | KDM5B (0.52) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL15637020 | 0.86 | KDM5B (0.45) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL15637432 | 0.86 | KDM5B (0.45) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL16296605 | 0.85 | KDM5B (0.44) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL15994238 | 0.84 | KDM5B (0.43) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL15636770 | 0.84 | KDM5B (0.47) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL15994187 | 0.83 | KDM5B (0.43) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL21716657 | 0.83 | KDM5B (0.52) | KDM5BKDM5CKDM5AKDM4CKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382865-A1 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382865-A1 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| CN-107434803-B | Inhibitors of histone demethylases | 吉利德科学公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2020033377-A1 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| US-10221139-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10189787-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3023415-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| EP-3150582-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9611219-B2 | — | — | 2017-04-04 | — | — | US | disclosed |
| US-9611220-B2 | — | — | 2017-04-04 | — | — | US | disclosed |
| EP-2903968-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-3023415-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2016-05-25 | — | — | EP | disclosed |
| EP-2903968-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2015-08-12 | — | — | EP | disclosed |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014053491-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382865-A1 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | KDM5A, KDM5B, KDM5C | KDM5B 2/4885KDM5C 3/4885KDM5A 1/4885 |
| US-10189787-B2 | Inhibitors of histone demethylases | EHMT1, KDM1B, EHMT2 | KDM5B 34/4885KDM5C 31/4885KDM5A 24/4885 |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | KDM5B 34/4885KDM5C 31/4885KDM5A 25/4885 |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | KDM5B 34/4885KDM5C 31/4885KDM5A 24/4885 |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | KDM5B 34/4885KDM5C 31/4885KDM5A 24/4885 |
| US-10221139-B2 | Inhibitors of histone demethylases | EHMT1, KDM1B, EHMT2 | KDM5B 34/4885KDM5C 31/4885KDM5A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.